iBio Q2 FY2025 net loss $4.4M; cash $7.2M; advances pipeline

iBio, Inc.

2025-Q2 EPS reported -$0.94 vs consensus -$0.37 ▼ miss (-152.5%)

Revenue $0.2M; net loss $4.4M ($0.48/shr) vs $4.5M ($2.42/shr) prior year.
Cash & equivalents $7.2M as of Dec 31, 2024, including $0.2M restricted.
Discovered novel Activin E antibody; in-licensed anti-myostatin IBIO-600 in Jan 2025.
Initiated bispecific myostatin/activin A program; plans clinical investigation in 2026.
Board added David Arkowitz and António Parada; insider private placement closed Jan 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.